Neurotoxicity Research

, Volume 9, Issue 1, pp 47–57

Methylene blue prevents neurodegeneration caused by rotenone in the retina

Article

Abstract

An experimental optic neuropathy model was used to test the hypothesis that methylene blue may protect the retinal ganglion cell layer from neurodegeneration caused by rotenone. Rotenone is a widely used pesticide that inhibits complex I, the first enzyme of the mitochondrial respiratory chain. Complex I dysfunction is linked to the degeneration of retinal ganglion cells in Leber’s optic neuropathy. Methylene blue is a reduction-oxidation agent that can act as a powerful antioxidant and also as an enhancer of the electron transport chain, preventing formation of mitochondrial oxygen free radicals and promoting oxygen consumption. The neurodegeneration of the retina was studied in mice with intravitreal microinjection of rotenone alone, or in combination with increasing doses of methylene blue, in one eye, and the vehicle in the contralateral control eye. The effect of rotenone and rotenone plus methylene blue was investigated using two histological stains, complex I and Nissl, and two measurements, morphometric layer thickness and non-biased stereological cell counts. Rotenone induced neurodegeneration in the retinal ganglion cell layer 24 h after injection, as indicated by significant reductions in both the thickness and cell numbers of the retinal ganglion cell layer of eyes microinjected with rotenone as compared to the control eyes. This neurodegeneration was prevented in a dose dependent manner by the injection of methylene blue along with rotenone. It was concluded that rotenone-induced degeneration in the ganglion cell layer can be prevented by intravitreal injection of methylene blue.In vitro experiments showed that methylene blue is both a powerful antioxidant as well as an enhancer of cellular oxygen consumption and is able to reverse the oxidative stress and decrease in oxygen consumption induced by rotenone in brain homogenates. The findings suggest that methylene blue may be a promising neuroprotective agent in optic neuropathy and perhaps other neurodegenerative diseases caused by mitochondrial dysfunction.

Keywords

Methylene blue Rotenone Neurodegeneration Neuroprotection Optic neuropathy 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Beal MF (1998) Mitochondrial dysfunction in neurodegenerative diseases.Biochim. Biophys. Acta (BBA) — Bioenergetics 1366, 211–223.CrossRefGoogle Scholar
  2. Betarbet R, TB Sherer, G MacKenzie, M Garcia-Osuna, AV Panov and JT Greenamyre (2000) Chronic systemic pesticide exposure reproduces features of Parkinson’s disease.Nat. Neurosci. 3, 1301–1306.PubMedCrossRefGoogle Scholar
  3. Bradberry SM (2003) Occupational methaemoglobinaemia. Mechanisms of production, features, diagnosis and management including the use of methylene blue.Toxicol. Rev. 22, 13–27.PubMedCrossRefGoogle Scholar
  4. Brown MD, AS Voljavec, MT Lott, I MacDonald and DC Wallace (1992) Leber’s hereditary optic neuropathy: A model for mitochondrial neurodegenerative diseases.FASEB J. 6,2791–2799.PubMedGoogle Scholar
  5. Callaway NL, PD Riha, KM Wrubel, D McCollum and F Gonzalez-Lima (2002) Methylene blue restores spatial memory retention impaired by an inhibitor of cytochrome oxidase in rats.Neurosci. Lett. 332, 83–86.PubMedCrossRefGoogle Scholar
  6. Callaway NL, PD Riha, AK Bruchey, Z Munshi and F Gonzalez-Lima (2004) Methylene blue improves brain oxidative metabolism and memory retention in rats.Pharmacol. Biochem. Behav. 77, 175–181.PubMedCrossRefGoogle Scholar
  7. Chen TA, F Yang, GM Cole and SO Chan (2001) Inhibition of caspase-3-like activity reduces glutamate induced cell death in adult rat retina.Brain Res. 904, 177–188.PubMedCrossRefGoogle Scholar
  8. Choi DW (1988) Glutamate neurotoxicity and diseases of the nervous system.Neuron 1, 623–634.PubMedCrossRefGoogle Scholar
  9. Choi DW (1995) Calcium: still center-stage in hypoxic-ischemic neuronal death.Trends Neurosci. 18, 58–60.PubMedCrossRefGoogle Scholar
  10. Cleeter MW, JM Cooper and AH Schapira (1992) Irreversible inhibition of mitochondrial complex I by 1-methyl-4-phenylpyridinium: evidence for free radical involvement.J. Neurochem. 58, 786–789.PubMedCrossRefGoogle Scholar
  11. Clifton J and JB Leikin (2003) Methylene blue.Am. J. Ther. 10, 289–291.PubMedCrossRefGoogle Scholar
  12. Coyle JT and P Puttfarcken (1993) Oxidative stress, glutamate, and neurodegenerative disorders.Science 262, 689–695.PubMedCrossRefGoogle Scholar
  13. Degli Esposti M (1998) Inhibitors of NADH-ubiquinone reductase: an overview.Biochim. Biophys. Acta (BBA) — Bioenergetics 1364, 222–235.CrossRefGoogle Scholar
  14. Drager UC and JF Olsen (1981) Ganglion cell distribution in the retina of the mouse. Invest.Ophthalmol. Vis. Sci. 20, 285–293.Google Scholar
  15. Dreyer EB, D Zurakowski, RA Schumer, SM Podos and SA Lipton (1996) Elevated glutamate levels in the vitreous body of humans and monkeys with glaucoma.Arch. Ophthalmol. 114, 299–305.PubMedGoogle Scholar
  16. Duarte CB, IL Ferreira, PF Santos, AL Carvalho, PM Agostinho and AP Carvalho (1998) Glutamate in life and death of retinal amacrine cells.Gen. Pharmacol. 30, 289–295.PubMedCrossRefGoogle Scholar
  17. Gonzalez-Lima F and A Cada (1994) Cytochrome oxidase activity in the auditory system of the mouse: a qualitative and quantitative histochemical study.Neuroscience 63, 559–578.PubMedCrossRefGoogle Scholar
  18. Gonzalez-Lima F and A Cada (1998) Quantitative histochemistry of cytochrome oxidase activity, In:Cytochrome Oxidase in Neuronal Metabolism and Alzheimer’s Disease (Gonzalez-Lima F, Ed.) (Plenum Press: New York, NY), 55–90.Google Scholar
  19. Gonzalez-Lima F and D Jones (1994) Quantitative mapping of cytochrome oxidase activity in the central auditory system of the gerbil: a study with calibrated activity standards and metal-intensified histochemistry.Brain Res. 660, 34–49.PubMedCrossRefGoogle Scholar
  20. Gonzalez-Lima F, J Valla and S Matos-Collazo (1997) Quantitative cytochemistry of cytochrome oxidase and cellular morphometry of the human inferior colliculus in control and Alzheimer’s patients.Brain Res. 752, 117–126.PubMedCrossRefGoogle Scholar
  21. Gonzalez-Lima F, J Valla and L Jorandby (1998) Cytochrome oxidase inhibition in Alzheimer’s disease, In:Cytochrome Oxidase in Neuronal Metabolism and Alzheimer’s Disease (Gonzalez-Lima F, Ed.) (Plenum Press: New York, NY), 171–200.Google Scholar
  22. Gunasekar PG, AG Kanthasamy, JL Borowitz and GE Isom (1995) NMDA receptor activation produces concurrent generation of nitric oxide and reactive oxygen species: implications for cell death.J. Neurochem. 65, 2016–2021.PubMedCrossRefGoogle Scholar
  23. Hassan HM and I Fridovich (1979) Intracellular production of superoxide radical and of hydrogen peroxide by redox active compounds.Arch. Biochem. Biophys. 196, 385–395.PubMedCrossRefGoogle Scholar
  24. Howell N (1998) Leber hereditary optic neuropathy: Respiratory chain dysfunction and degeneration of the optic nerve.Vision Res. 38, 1495–1504.PubMedCrossRefGoogle Scholar
  25. Jung C, CMJ Higgins and Z Xu (2002) A quantitative histochemical assay for activities of mitochondrial electron transport chain complexes in mouse spinal cord sections.J. Neurosci. Methods 114, 165–172.PubMedCrossRefGoogle Scholar
  26. Kelner MJ, R Bagnell, B Hale and NM Alexander (1988) Potential of methylene blue to block oxygen radical generation in reperfusion injury.Basic Life Sci. 49, 895–898.PubMedGoogle Scholar
  27. Kupfer A, C Aeschlimann and T Cerny (1996) Methylene blue and the neurotoxic mechanisms of ifosfamide encephalopathy.Eur. J. Clin. Pharmacol. 50, 249–252.PubMedCrossRefGoogle Scholar
  28. Lafon-Cazal M, S Pietri, M Culcasi and J Bockaert (1993) NMDA-dependent superoxide production and neurotoxicity.Nature 364, 535–537.PubMedCrossRefGoogle Scholar
  29. Lee MJ, FP Chou, TH Tseng, MH Hsieh, MC Lin and CJ Wang (2002) Hibiscus protocatechuic acid or esculetin can inhibit oxidative LDL induced by either copper ion or nitric oxide donor.J. Agric. Food Chem. 50, 2130–2136.PubMedCrossRefGoogle Scholar
  30. Lindahl PE and KE Oberg (1961) The effect of rotenone on respiration and its point of attack.Exp. Cell Res. 23, 228.PubMedCrossRefGoogle Scholar
  31. Martinez JL Jr, RA Jensen, BJ Vasquez, T McGuinness and JL McGaugh (1978) Methylene blue alters retention of inhibitory avoidance responses.Physiol. Psychol.6, 387–390.Google Scholar
  32. Mattson MP (2003) Excitotoxic and excitoprotective mechanisms: abundant targets for the prevention and treatment of neurode-generative disorders.Neuromolecular Med. 3, 65–94.PubMedCrossRefGoogle Scholar
  33. Mayer B, F Brunner and K Schmidt (1993) Inhibition of nitric oxide synthesis by methylene blue.Biochem. Pharmacol. 45, 367–374.PubMedCrossRefGoogle Scholar
  34. Naylor GJ, B Maton, SE Hopwood and Y Watson (1986) A two-year double-blind crossover trial of the prophylactic effect of methylene blue in manic-depressive psychosis.Biol. Psychiatry 21, 915–920.PubMedCrossRefGoogle Scholar
  35. Nobrega J, R Raymond, L DiStefano and WM Burnham (1993) Long-term changes in regional brain cytochrome oxidase activity induced by electroconvulsive treatment in rats.Brain Res. 605, 1–8.PubMedCrossRefGoogle Scholar
  36. O’Leary JL, J Petty, AB Harris and J Inukai (1968) Supravital staining of mammalian brain with intra-arterial methylene blue followed by pressurized oxygen.Stain Technol. 43, 197–201.PubMedGoogle Scholar
  37. Peter C, D Hongwan, A Kupfer and BH Lauterburg (2000) Pharmacokinetics and organ distribution of intravenous and oral methylene blue.Eur. J. Clin. Pharmacol. 56, 247–250.PubMedCrossRefGoogle Scholar
  38. Richardson KC (1969) The fine structure of autonomic nerves after vital staining with methylene blue.Anat. Rec. 164, 359–377.PubMedCrossRefGoogle Scholar
  39. Riha PD, AK Bruchey, DJ Echevarria and F Gonzalez-Lima (2005) Memory facilitation by methylene blue: dose-dependent effect on behavior and brain oxygen consumption.Eur. J. Pharmacol. 511, 151–158.PubMedCrossRefGoogle Scholar
  40. Salaris SC, CF Babbs and CE Voorhees III (1991) Methylene blue as an inhibitor of superoxide generation by xanthine oxidase: a potential new drug for the attenuation of ischemia/reperfusion injury.Biochem. Pharmacol. 42, 499–506.PubMedCrossRefGoogle Scholar
  41. Schapira AHV (1998) Human complex I defects in neurodegenerative diseases.Biochim. Biophys. Acta (BBA) — Bioenergetics 1364, 261–270.CrossRefGoogle Scholar
  42. Sherer TB, JH Kim, R Betarbet and JF Greenamyre (2003) Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and [alpha]-synuclein aggregation.Exp. Neurol. 179, 9–16.PubMedCrossRefGoogle Scholar
  43. Singer TP and RR Ramsay (1994) The reaction sites of rotenone and ubiquinone with mitochondrial NADH dehydrogenase.Biochim. Biophys. Acta (BBA) — Bioenergetics 1187, 198–202.CrossRefGoogle Scholar
  44. United States National Toxicology Program (1990) Chemical Status Report. NTP Chemtrack System.Google Scholar
  45. Valla J, K Chen, JD Berndt, F Gonzalez-Lima, SR Cherry, D Games and EM Reiman (2002) Effects of image resolution on autoradiographic measurements of posterior cingulate activity in PDAPP mice: implications for functional nrain imaging studies of transgenic mouse models of Alzheimer’s disease.NeuroImage 16, 1–6.PubMedCrossRefGoogle Scholar
  46. Visarius TM, JW Stucki and H Bernhard (1997) Stimulation of respiration by methylene blue in rat liver mitochondria.FEBS Lett. 412, 157–160.PubMedCrossRefGoogle Scholar
  47. Wainwright M and KB Crossley (2002) Methylene blue—a therapeutic dye for all seasons?J. Chemother. 14, 431–443.PubMedGoogle Scholar
  48. Wong-Riley MT (1989) Cytochrome oxidase: an endogenous metabolic marker for neuronal activity.Trends Neurosci. 12, 94–101.PubMedCrossRefGoogle Scholar
  49. Zhang X, D Jones and F Gonzalez-Lima (2002) Mouse model of optic neuropathy caused by mitochondrial complex I dysfunction.Neurosci. Lett. 326, 97–100.PubMedCrossRefGoogle Scholar
  50. Zhang Y, O Marcillat, C Giulivi, L Ernster and KJ Davies (1990) The oxidative inactivation of mitochondrial electron transport chain components and ATPase.J. Biol. Chem. 265, 16330–16336.PubMedGoogle Scholar

Copyright information

© Springer 2006

Authors and Affiliations

  1. 1.Institute for NeuroscienceUniversity of Texas at AustinAustinUSA
  2. 2.Departments of Psychology, Pharmacology and ToxicologyUniversity of Texas at AustinAustinUSA

Personalised recommendations